home / stock / aezs:cc / aezs:cc news

AEZS:CC News and Press, Aeterna Zentaris Inc. From 05/16/22

Stock Information
Company Name: Aeterna Zentaris Inc.
Stock Symbol: AEZS:CC
Market: TSXC
Website: zentaris.com
Menu
AEZS:CC AEZS:CC Quote AEZS:CC Short AEZS:CC News AEZS:CC Articles AEZS:CC Message Board
Get AEZS:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
AEZS:CC - Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation

TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ” or the “ Company ”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced th...
AEZS:CC - Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's Disease

– Data presented at IMMUNOLOGY2022 ™ , the A nnual Event of the American Association of Immunologists – Company advancing development of its Autoimmunity Modifying ( “ AIM &#x...

AEZS:CC - Aeterna Zentaris Reports First Quarter 2022 Financial Results and Provides Business Outlook

– C ontinue d advancement across di versified development pipeline – Company ended the quarter with $ 6 3 . 6 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, M...

AEZS:CC - Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022(TM), the Annual Event of the American Association of Immunologists

– Company advancing development of its Autoimmunity Modifying AIM Biologic al s as a potential therapeutic treatment option for Parkinson’s Disease (" PD "), a neurodegenerative movement disorder TORONTO, ON...
AEZS:CC - Aeterna Zentaris Secures New European Patent Related to Use of Macimorelin for the Diagnosis of Growth Hormone Deficiency in Adults

– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin ® / Macrilen ™ in Europe as the Company plans to pursue even greater protection TORONTO, ONTARIO, April...

AEZS:CC - Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight

– Live moderated video webcast fireside chat with Dr. Klaus Paulini , CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday , April 14th at 10 :00 AM ET TORONTO, ONTARIO, April 12, 2022 (GLOBE NEWSWI...

AEZS:CC - Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity

– Company to present regarding AIM Biologic al s as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need TORONTO, ONTARIO, April 11, 2022 (GLOBE...
AEZS:CC - Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook

– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, March 29, 2022 (GLOBE NEWSWIRE) -- Aeterna...

AEZS:CC - Aeterna Zentaris Provides Update on Ongoing Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient enrollment expected to continue into 2023 TO...

Previous 10 Next 10